454 Sequencing Systems and NimbleGen Sequence Capture Show Promise for Genetic Characterization of Leukemia

This week at the 51st American Society for Hematology Annual Meeting, a team of researchers from the MLL Munich Leukemia Laboratory presented results from a series of groundbreaking studies which explore alternative, high-throughput 454 Sequencing methods for distinguishing and characterizing the many forms of leukemia and myeloproliferative disorders. Using targeted resequencing techniques from Roche Applied Science (Pink Sheets:RHHBY) (SWX:RO) (SWX:ROG), including NimbleGen Sequence Capture arrays and 454 Life Science's GS FLX System, the researchers were able to successfully detect all types of molecular mutations identified by conventional methods and, in addition, identify novel...

Want to see the full article?

• Purchase this article for only $3.00